Nanoview Biosciences

What Nanoview Biosciences does

Nanoview Biosciences, Inc. is a privately held Delaware-incorporated biotechnology company headquartered in Boston, Massachusetts, founded in 2015. The company develops proprietary extracellular vesicle (exosome) characterization and analysis technology targeting biotech and life-sciences customers developing exosome-based therapeutics, liquid-biopsy diagnostics, and minimally invasive disease-detection tools. Its core platform addresses the need for reliable EV-based biomarker analysis in research and translational workflows serving biotechnology companies and academic research institutions.

The company has funded its development through a mix of institutional venture rounds (Esco Ventures, Northpond Ventures, PBM Capital Group, Sands Capital Ventures), non-dilutive federal grants from the National Science Foundation, and state-level awards from MassVentures, aggregating to roughly $25 million in disclosed capital since inception. In December 2016 it acquired Nexgen Arrays to consolidate array-based detection capabilities into its exosome workflow. The company is led scientifically by founder and CSO George Daaboul and operationally by president and COO David Freedman.

Nanoview competes in a life-science research-tools market where rivals such as Unchained Labs have launched interferometry- and immunofluorescence-based EV characterization instruments (Leprechaun). No public pricing, distribution channels, named customers, or product-line details are disclosed in available sources. The most recent capital event was a February 2022 SEC Form D exempt offering targeting up to $5 million, indicating the company remains in an extended development and pre-clinical-commercialization stage within a regulatory environment where no FDA-approved exosome products yet exist.

Name

Nanoview Biosciences

Legal name

NanoView Biosciences, Inc.

Website

https://nanoviewbio.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Nanoview Biosciences is a Boston-based private biotechnology company developing proprietary extracellular vesicle (exosome) characterization and analysis technology for biotech firms and research institutions working on liquid-biopsy diagnostics and exosome-based therapeutics.

Ownership category

akta.pro rank

Product category

Extracellular Vesicle Analysis Instruments

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)

akta.pro secondary industries

Proteomics & Biomarker Analytical Testing (HLAGADAG), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• Exosome characterization
• Extracellular vesicle analysis
• Liquid biopsy diagnostics
• Biomarker discovery
• Precision medicine tools

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Core offering

Nanoview Biosciences develops proprietary products that support research, translation, and delivery of precision medicine, with a core focus on extracellular vesicle (exosome) characterization and analysis technology for biotechnology applications. The company's tools are used by developers of exosome-based therapeutics and diagnostics, as well as research institutions working on minimally invasive diagnostic tools such as liquid biopsy for cancer detection.

Differentiator

Problem solved

Functional benefit

Products and services

• Extracellular Vesicle (Exosome) Characterization and Analysis Platform Proprietary technology platform for exosome characterization and analysis that supports minimally invasive diagnostic development and exosome-based biomarker analysis for disease detection and research. Targeted at biotechnology and life sciences companies developing exosome-based therapeutics and diagnostics, and at research institutions in the extracellular vesicle field.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• Unchained Labs: Direct competitor in EV characterization. Unchained Labs' Leprechaun instrument uses interferometry and immunofluorescence to characterize extracellular vesicles and lentiviruses, overlapping with Nanoview's core exosome analysis platform for biopharma and academic customers.
• Particle Metrix: Manufactures Nanoparticle Tracking Analysis (ZetaView) systems widely used for exosome concentration and size distribution. Strong overlap with Nanoview's EV characterization value proposition.
• Izon Science: Provides tunable resistive pulse sensing (TRPS) instruments for extracellular vesicle and nanoparticle characterization. Direct overlap with Nanoview's EV sizing and quantification applications for research and translational customers.
• NanoFCM: Commercializes nano-flow cytometry instruments specifically designed for single-EV analysis. Competes head-to-head with Nanoview on EV sizing, phenotyping, and quantification workflows in academic and biotech labs.
• System Biosciences (SBI): Specializes in exosome research tools, including isolation kits, EV characterization reagents, and engineered exosome services. Highly comparable niche focus on the same extracellular-vesicle research customer base.

Broad incumbents

• Bio-Techne: Large, diversified life-science tools incumbent with exosome research reagents, ExoDx diagnostic products, and protein analysis kits. Comparable because Bio-Techne sells into the same EV/biomarker research workflows Nanoview targets, but as part of a much broader portfolio.
• Lonza Group: Global CDMO with exosome manufacturing services and cell/gene therapy capabilities. Comparable because Lonza serves overlapping biopharma customers developing EV-based therapeutics and offers adjacent analytical services.
• Roche Diagnostics: Major diagnostics incumbent with established liquid biopsy franchises (Foundation Medicine, ctDNA assays). Represents the strategic endpoint Nanoview's biomarker-analysis capabilities could feed into via partnership or acquisition.
• Beckman Coulter Life Sciences: Provides high-sensitivity flow cytometry platforms used for EV characterization and biomarker discovery. Comparable because Beckman Coulter sells analytical instrumentation into the same translational EV research workflows Nanoview serves.

Emerging players

• Exosomics Siena: Focused on EV-based liquid biopsy diagnostics and proprietary isolation/characterization technology. Comparable as a smaller, EV-focused peer pursuing the same translational diagnostic opportunity.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/nanoviewbio
• LinkedInlinkedin.com/company/nanoview-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds8 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanoview Biosciences